About Beta-Ala-His dipeptidase
Beta-Ala-His dipeptidase (CNDP1) is a protein
from Homo sapiens identified by UniProt accession
Q96KN2, 507 residues long.
MolForge cross-references it against 0 known binders and
115 disease associations.
Target properties
| Protein name | Beta-Ala-His dipeptidase |
| UniProt accession | Q96KN2 |
| Gene | CNDP1 |
| Organism | Homo sapiens |
| Length | 507 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (115)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.48
- neurodegenerative disease · score 0.37
- beta-Ala-His dipeptidase measurement · score 0.32
- hepatocellular carcinoma · score 0.10
- liver dysplastic nodule · score 0.08
- cancer · score 0.08
- metabolite measurement · score 0.08
- body height · score 0.08
- diabetic nephropathy · score 0.07
- Barrett's esophagus · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96KN2-F1 | alphafold | PREDICTED | 93.98 | — |
Amino-acid sequence (507 residues)
MDPKLGRMAA SLLAVLLLLL ERGMFSSPSP PPALLEKVFQ YIDLHQDEFV QTLKEWVAIE SDSVQPVPRF RQELFRMMAV AADTLQRLGA RVASVDMGPQ QLPDGQSLPI PPVILAELGS DPTKGTVCFY GHLDVQPADR GDGWLTDPYV LTEVDGKLYG RGATDNKGPV LAWINAVSAF RALEQDLPVN IKFIIEGMEE AGSVALEELV EKEKDRFFSG VDYIVISDNL WISQRKPAIT YGTRGNSYFM VEVKCRDQDF HSGTFGGILH EPMADLVALL GSLVDSSGHI LVPGIYDEVV PLTEEEINTY KAIHLDLEEY RNSSRVEKFL FDTKEEILMH LWRYPSLSIH GIEGAFDEPG TKTVIPGRVI GKFSIRLVPH MNVSAVEKQV TRHLEDVFSK RNSSNKMVVS MTLGLHPWIA NIDDTQYLAA KRAIRTVFGT EPDMIRDGST IPIAKMFQEI VHKSVVLIPL GAVDDGEHSQ NEKINRWNYI EGTKLFAAFF LEMAQLH
Explore Beta-Ala-His dipeptidase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets